Market Chameleon (Tue, 18-Aug 3:06 AM ET)
Jones Served as Sole Book-Running Manager for Vogenx's $81.3 Million Initial Public Offering
PRNewswire (Mon, 17-Aug 12:26 PM ET)
Vogenx Announces Closing of Initial Public Offering
ACCESS Newswire (Thu, 13-Aug 4:35 PM ET)
Vogenx Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia, or PBH, and gastroparesis. The company's flagship product candidate, mizagliflozin, is an orally administered, minimally absorbed, small molecule drug candidate being developed for the treatment of post-bariatric hypoglycemia (PBH), gastroparesis and GIP-induced Cushing's Syndrome. It operates as a single reportable segment engaged in the discovery and development of treatments for serious metabolic and gastrointestinal diseases.
Vogenx trades on the NASDAQ stock market under the symbol VOGX.
As of August 28, 2026, VOGX stock price climbed to $33.96 with 38,087 million shares trading.
VOGX has a market cap of $504.48 million. This is considered a Small Cap stock.
VOGX support price is $28.56 and resistance is $38.70 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that VOGX shares will trade within this expected range on the day.